Approved for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy, and for KRAS G12C-mutated metastatic colorectal cancer (in combination with cetuximab) after prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.